217 related articles for article (PubMed ID: 28739703)
1. Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
Tamiya A; Tamiya M; Nishihara T; Shiroyama T; Nakao K; Tsuji T; Takeuchi N; Isa SI; Omachi N; Okamoto N; Suzuki H; Okishio K; Iwazaki A; Imai K; Hirashima T; Atagi S
Anticancer Res; 2017 Aug; 37(8):4177-4182. PubMed ID: 28739703
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.
Hoffknecht P; Tufman A; Wehler T; Pelzer T; Wiewrodt R; Schütz M; Serke M; Stöhlmacher-Williams J; Märten A; Maria Huber R; Dickgreber NJ;
J Thorac Oncol; 2015 Jan; 10(1):156-63. PubMed ID: 25247337
[TBL] [Abstract][Full Text] [Related]
3. Activity of afatinib in patients with NSCLC harboring novel uncommon
Christopoulos P; Herster F; Hoffknecht P; Falk M; Tiemann M; Kopp HG; Althoff A; Stammberger A; Laack E
Front Oncol; 2024; 14():1347742. PubMed ID: 38769948
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.
Miao Q; Zheng X; Li L; Zheng X; Zhang L; Jiang K; Wu S; Wang H; Wu B; Xu Y; Zhong Q; Zou Z; Zhang Q; Yang S; Li Y; Lin G
J Neurooncol; 2023 Dec; 165(3):517-525. PubMed ID: 38104049
[TBL] [Abstract][Full Text] [Related]
5. Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam.
Pham VL; Le TA; Pham CP; Hoa Nguyen TT; Do AT; Nguyen TK; Nguyen MH; Thu Hoang TA; Hao Vuong DT; Tam Nguyen DN; Khiem Dang V; Nguyen TO; Trang Vo TH; Do HK; Vu HT; Nguyen TTH; Pham VT; Trinh LH; Dung Nguyen K; Nguyen HG; Truong CM; Chau Pham TM; Nguyen TBP
Ther Adv Med Oncol; 2024; 16():17588359241242972. PubMed ID: 38736554
[TBL] [Abstract][Full Text] [Related]
6. Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation.
Kuo CS; Chiu TH; Tung PH; Huang CH; Ju JS; Huang AC; Wang CC; Ko HW; Hsu PC; Fang YF; Guo YK; Yang CT
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053480
[TBL] [Abstract][Full Text] [Related]
7. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.
Chang AEB; Piper-Vallillo AJ; Mak RH; Lanuti M; Muzikansky A; Rotow J; Jänne PA; Mino-Kenudson M; Swanson S; Wright CD; Kozono D; Marcoux P; Piotrowska Z; Sequist LV; Willers H
Oncologist; 2024 May; ():. PubMed ID: 38761385
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer.
Chiu LC; Hsu PC; Wang CC; Ko HW; Kuo SC; Ju JS; Tung PH; Huang AC; Yang CT
Thorac Cancer; 2024 Mar; 15(7):529-537. PubMed ID: 38279515
[TBL] [Abstract][Full Text] [Related]
9. A Lung Adenocarcinoma Patient With a Rare
Wei Y; Cui Y; Guo Y; Li L; Zeng L
Front Oncol; 2021; 11():700345. PubMed ID: 34178699
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases.
Liu X; Mei F; Fang M; Jia Y; Zhou Y; Li C; Tian P; Lu C; Li G
Front Oncol; 2023; 13():1322635. PubMed ID: 38269023
[TBL] [Abstract][Full Text] [Related]
11. Does dose reduction of afatinib affect treatment outcomes of patients with
Poh ME; Chai CS; Liam CK; Ho GF; Pang YK; Hasbullah HH; Tho LM; Muhamad Nor I; Ho KF; Thiagarajan M; Samsudin A; Omar A; Ong CK; Soon SY; Tan SN; How SH
Transl Lung Cancer Res; 2024 Feb; 13(2):307-320. PubMed ID: 38496703
[TBL] [Abstract][Full Text] [Related]
12. Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report.
Long X; Qin T; Lin J
Onco Targets Ther; 2020; 13():10689-10692. PubMed ID: 33116645
[TBL] [Abstract][Full Text] [Related]
13. Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations.
Chang GC; Lam DC; Tsai CM; Chen YM; Shih JY; Aggarwal S; Wang S; Kim SW; Kim YC; Wahid I; Li R; Lim DW; Sriuranpong V; Chan RT; Lorence RM; Carriere P; Raabe C; Cseh A; Park K
Int J Clin Oncol; 2021 May; 26(5):841-850. PubMed ID: 33783657
[TBL] [Abstract][Full Text] [Related]
14. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases.
Kumthekar P; Tang SC; Brenner AJ; Kesari S; Piccioni DE; Anders C; Carrillo J; Chalasani P; Kabos P; Puhalla S; Tkaczuk K; Garcia AA; Ahluwalia MS; Wefel JS; Lakhani N; Ibrahim N
Clin Cancer Res; 2020 Jun; 26(12):2789-2799. PubMed ID: 31969331
[TBL] [Abstract][Full Text] [Related]
15. Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With
Ninomaru T; Okada H; Fujishima M; Irie K; Fukushima S; Hata A
JTO Clin Res Rep; 2021 Mar; 2(3):100145. PubMed ID: 34590003
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors.
Barbour AB; Blouw B; Taylor LP; Graber JJ; McGranahan T; Blau M; Halasz LM; Lo SS; Tseng YD; Venur V; Yang JT
J Neurooncol; 2024 May; 167(3):509-514. PubMed ID: 38441840
[TBL] [Abstract][Full Text] [Related]
17. Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes.
Baccili Cury Megid T; Baskurt Z; Ma LX; Barron CC; Farooq A; Saltiel MP; Wang X; Bach Y; Ayoama H; Jang RW; Chen E; Veit-Haibach P; Wang B; Kalimuthu S; Cotton J; Wong R; Mesci A; Elimova E
J Neurooncol; 2024 Mar; 167(1):111-122. PubMed ID: 38372902
[TBL] [Abstract][Full Text] [Related]
18. Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis.
Azad TD; Nanjo S; Jin MC; Chabon JJ; Kurtz DM; Chaudhuri AA; Connolly ID; Hui AB; Liu CL; Merriott D; Ko R; Yoo C; Carter J; Chen E; Bonilla R; Hata A; Katakami N; Irie K; Yano S; Okimoto R; Bivona TG; Newman AM; Iv M; Nagpal S; Gephart MH; Alizadeh AA; Diehn M
NPJ Precis Oncol; 2024 May; 8(1):121. PubMed ID: 38806586
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of slow-rate ventriculolumbar perfusion chemotherapy for leptomeningeal carcinomatosis: a phase II study.
Jang S; Gwak HS; Joo J; Doh YS; Shin SH; Yoo H; Wang KC
Acta Neurochir (Wien); 2024 Mar; 166(1):117. PubMed ID: 38424255
[TBL] [Abstract][Full Text] [Related]
20. New Breakthroughs in the Diagnosis of Leptomeningeal Carcinomatosis: A Review of Liquid Biopsies of Cerebrospinal Fluid.
Goldberg M; Mondragon-Soto MG; Altawalbeh G; Meyer B; Aftahy AK
Cureus; 2024 Feb; 16(2):e55187. PubMed ID: 38558729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
